Serum osteoprotegerin levels are related to height loss: The Tromsø Study

European Journal of Epidemiology

Volumn 26, Issue 4, 2011, Pages 305-312

  Jørgensen, Lone ^a,b   Hansen, John Bjarne ^a   Brox, Jan ^a,b   Mathiesen, Ellisiv ^a,b   Vik, Anders ^a   Jacobsen, Bjarne K ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Epidemiology; Height loss; Nuclear factor kB ligand; Osteoporosis; Osteoprotegerin

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; NORWAY; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

AGED; ANTHROPOMETRY; BODY HEIGHT; FEMALE; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; MALE; MENOPAUSE; MIDDLE AGED; NORWAY; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 79959707162     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-011-9555-8     Document Type: Article

References (49)

1. Gunnes M, Lehmann EH, Mellstrøm D, Johnell O. The relationship between anthropometric measurements and fractures in women. Bone. 1996;19(4):407-13. (Pubitemid 26370844)
2. Tobias JH, Hutchinson AP, Hunt LP, McCloskey EV, Stone MD, Martin JC, et al. Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporos Int. 2007;18(1):35-43. (Pubitemid 44885494)
3. Krege JH, Siminoski K, Adachi JD, Misurski DA, Chen P. A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis. Osteoporos Int. 2006;17(3):379-86.
4. Siminoski K, Jiang G, Adachi JD, Hanley DA, Cline G, Ioannidis G, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005;16(4):403-10.
5. Siminoski K, Warshawski RS, Jen H, Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int. 2006;17(2):290-6. (Pubitemid 43053594)
6. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int. 1999;9(3):206-13.
7. Huang C, Ross PD, Lydick E, Davis JW, Wasnich RD. Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii. J Bone Miner Res. 1996;11(3):408-11. (Pubitemid 26076391)
8. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050-5. (Pubitemid 33131929)
9. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-8.
10. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. 1998;95(7):3597-602.
11. Vega D, Maalouf NM, Sakhaee K. CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92(12):4514-21. (Pubitemid 350223419)
12. Sorkin JD, Muller DC, Andres R. Longitudinal change in the heights of men and women: consequential effects on body mass index. Epidemiol Rev. 1999;21(2):247-60. (Pubitemid 30649826)
13. Drøyvold WB, Nilsen TI, Krûger O, Holmen TL, Krokstad S, Midthjell K, et al. Change in height, weight and body mass index: longitudinal data from the HUNT study in Norway. Int J Obes. 2006;30(6):935-9. (Pubitemid 43801193)
14. Forsmo S, Hvam HM, Rea ML, Lilleeng SE, Schei B, Langhammer A. Height loss, forearm bone density and bone loss in menopausal women: a 15-year prospective study. The Nord-Trøndelag Health Study, Norway. Osteoporos Int. 2007;18(9):1261-9.
15. Yoshimura N, Kinoshita H, Takijiri T, Oka H, Muraki S, Mabuchi A, et al. Association between height loss and bone loss, cumulative incidence of vertebral fractures and future quality of life: the Miyama study. Osteoporos Int. 2008;19(1):21-8. (Pubitemid 350198066)
16. Jørgensen L, Vik A, Emaus N, Brox J, Hansen JB, Mathiesen E, et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos Int. 2009;21(6):931-8.
17. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios LJ, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005;16(11):1368-74. (Pubitemid 41532089)
18. Jørgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab. 2004;22(2):132-8. (Pubitemid 38405042)
19. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631-7. (Pubitemid 32207471)
20. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004;291(9):1108-13. (Pubitemid 38541688)
21. Jørgensen L, Joakimsen O, Mathiesen EB, Ahmed L, Berntsen GK, Fønnebø V, et al. Carotid plaque echogenicity and risk of nonvertebral fractures in women: a longitudinal population-based study. Calcif Tissue Int. 2006;79(4):207-13. (Pubitemid 44673714)
22. McClung B, Parkins N, McClung MR. Comparison of height measurements made with Harpenden stadiometer and a wall-mounted ruler on patients with vertebral compressiom fractures. J Bone Miner Res. 1997;12(Suppl 1):S268.
23. Berntsen GK, Tollan A, Magnus JH, Søgaard AJ, Ringberg T, Fønnebø V. The Tromsø Study: artifacts in forearm bone densitometry-prevalence and effect. Osteoporos Int. 1999;10(5):425-32.
24. Berntsen GK, Fønnebø V, Tollan A, Søgaard AJ, Joakimsen RM, Magnus JH. The Tromsø study: determinants of precision in bone densitometry. J Clin Epidemiol. 2000;53(11):1104-12.
25. Auyeung TW, Lee JS, Leung J, Kwok T, Leung PC, Woo J. Effects of height loss on morbidity and mortality in 3145 community-dwelling Chinese older women and men: a 5-year prospective study. Age Ageing. 2010;39(6):699-704.
26. Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone. 2005;36(4):727-35.
27. Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol. 2005;62(3):349-53. (Pubitemid 40380417)
28. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005;16(4):417-23. (Pubitemid 40487400)
29. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002;13(5):394-9. (Pubitemid 34625396)
30. Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, et al. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause. 2008;15(2):357-62. (Pubitemid 351355000)
31. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32(6):681-6. (Pubitemid 37303940)
32. Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Z, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int. 2005;76(1):1-6. (Pubitemid 40228467)
33. Oh KW, Rhee EJ, Lee WY, Kim SW, Oh ES, Baek KH, et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol. 2004;61(2):244-9.
34. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002;87(10):4470-5. (Pubitemid 35247027)
35. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001;86(7):3162-5. (Pubitemid 32673481)
36. Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, et al. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest. 2008;31(2):163-8. (Pubitemid 351596978)
37. Samelson EJ, Broe KE, Demissie S, Beck TJ, Karasik D, Kathiresan S, et al. Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab. 2008;93(5):1789-95. (Pubitemid 351656519)
38. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111(19):2461-8. (Pubitemid 40696134)
39. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14(4):518-27. (Pubitemid 29153384)
40. Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol. 2005;62(1):92-8. (Pubitemid 40175289)
41. Stern A, Laughlin GA, Bergstrøm J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol. 2007;156(5):555-62. (Pubitemid 46796522)
42. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192(4):463-74. (Pubitemid 30666247)
43. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-23.
44. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-76. (Pubitemid 28180851)
45. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.
46. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95(1):3-10.
47. Mellström D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Oden A, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. 2008;23(10):1552-60.
48. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337-46.
49. Jiang G, Luo J, Pollintine P, Dolan P, Adams MA, Eastell R. Vertebral fractures in the elderly may not always be "osteoporotic". Bone. 2010;47(1):111-6.